We are live on
!
Find out more
GA
Geneva Advisors Portfolio holdings
AUM
$5.81B
Turnover
22.5%
1-Year Est. Return
23.71%
This Fund
S&P 500
This Quarter
Est. Return
+7.04%
1 Year Est. Return
+23.71%
3 Year Est. Return
+53.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.37B
AUM Growth
+$62.8M
(+1.2%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
20.35%
Holding
855
New
121
Increased
189
Reduced
310
Closed
120
Avg Time Held
1
year
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$45.7M |
| 2 |
Idexx Laboratories
IDXX
|
+$34.3M |
| 3 |
Cardinal Health
CAH
|
+$30.2M |
| 4 |
Applied Materials
AMAT
|
+$24.5M |
| 5 |
Elevance Health
ELV
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LyondellBasell Industries
LYB
|
+$73.1M |
| 2 |
Dover
DOV
|
+$41.7M |
| 3 |
SLB Ltd
SLB
|
+$40M |
| 4 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$38.2M |
| 5 |
Wynn Resorts
WYNN
|
+$35.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.73% |
| 2 | Financials | 15.53% |
| 3 | Industrials | 13.23% |
| 4 | Consumer Discretionary | 12.83% |
| 5 | Technology | 10.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
501
PEDEVCO
PED
$178M
| $247K | ﹤0.01% |
2,740
+588
| +27% | +$93.2K |
2013 Q3
5 quarters
|
|
502
Eaton
ETN
$156B
| $245K | ﹤0.01% |
3,611
-141
| -4% | -$9.3K |
2013 Q2
6 quarters
|
|
|
IMPV
503
DELISTED
Imperva, Inc.
IMPV
| $245K | ﹤0.01% |
+4,950
| New | +$198K |
2014 Q4
0 quarters
|
|
504
DELISTED
PLUM CREEK TIMBER CO (REIT)
PCL
| $245K | ﹤0.01% |
5,719
-1,505
| -21% | -$61.8K |
2013 Q2
6 quarters
|
|
505
Workday
WDAY
$46.9B
| $243K | ﹤0.01% |
+2,974
| New | +$257K |
2014 Q4
0 quarters
|
|
506
Schwab US Large- Cap ETF
SCHX
$74.6B
| $242K | ﹤0.01% |
29,562
| – | – |
2014 Q1
3 quarters
|
|
|
OKS
507
DELISTED
Oneok Partners LP
OKS
| $242K | ﹤0.01% |
6,115
-32,780
| -84% | -$1.55M |
2014 Q1
3 quarters
|
|
508
iShares Biotechnology ETF
IBB
$10.5B
| $241K | ﹤0.01% |
+2,385
| New | +$232K |
2014 Q4
0 quarters
|
|
|
PETX
509
DELISTED
Aratana Therapeutics, Inc.
PETX
| $238K | ﹤0.01% |
+13,358
| New | +$166K |
2014 Q4
0 quarters
|
|
|
HSEA.CL
510
DELISTED
HSBC Holdings plc
HSEA.CL
| $238K | ﹤0.01% |
9,000
| – | – |
2013 Q2
6 quarters
|
|
511
Allstate
ALL
$61.6B
| $236K | ﹤0.01% |
3,364
-304
| -8% | -$20K |
2013 Q4
4 quarters
|
|
512
Arthur J. Gallagher & Co
AJG
$65.2B
| $233K | ﹤0.01% |
4,941
-257
| -5% | -$12.1K |
2013 Q2
6 quarters
|
|
|
RDS.A
513
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $232K | ﹤0.01% |
3,712
+20
| +0.5% | +$1.29K |
2014 Q1
3 quarters
|
|
514
British American Tobacco
BTI
$128B
| $230K | ﹤0.01% |
+4,260
| New | +$239K |
2014 Q4
0 quarters
|
|
515
Clorox
CLX
$10.5B
| $229K | ﹤0.01% |
2,198
+1
| +0% | +$100 |
2014 Q2
2 quarters
|
|
516
Goldman Sachs
GS
$264B
| $228K | ﹤0.01% |
+1,175
| New | +$221K |
2014 Q4
0 quarters
|
|
517
Target
TGT
$72.2B
| $224K | ﹤0.01% |
2,955
-1,500
| -34% | -$101K |
2013 Q2
6 quarters
|
|
518
ProShares Ultra Financials
UYG
$766M
| $224K | ﹤0.01% |
+9,000
| New | +$208K |
2014 Q4
0 quarters
|
|
519
DELISTED
Discover Financial Services
DFS
| $223K | ﹤0.01% |
+3,407
| New | +$219K |
2014 Q4
0 quarters
|
|
520
State Street SPDR S&P Dividend ETF
SDY
$21.6B
| $223K | ﹤0.01% |
+2,829
| New | +$221K |
2014 Q4
0 quarters
|
|
521
Diamondback Energy
FANG
$55.4B
| $218K | ﹤0.01% |
+3,645
| New | +$232K |
2014 Q4
0 quarters
|
|
522
State Street Consumer Staples Select Sector SPDR ETF
XLP
$14.6B
| $218K | ﹤0.01% |
+4,502
| New | +$213K |
2014 Q4
0 quarters
|
|
|
SLXP
523
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $217K | ﹤0.01% |
1,885
-315,169
| -99% | -$38.2M |
2013 Q4
4 quarters
|
|
524
Conagra Brands
CAG
$6.86B
| $214K | ﹤0.01% |
+7,573
| New | +$207K |
2014 Q4
0 quarters
|
|
525
iShares Select Dividend ETF
DVY
$23.3B
| $214K | ﹤0.01% |
2,694
-255
| -9% | -$19.7K |
2014 Q1
3 quarters
|
|
Similar funds
CAM
DL
TCM
HCM
AL
AT
Geneva Advisors's Q4 2014 Portfolio in Review
As of Q4 2014, Geneva Advisors held 855 positions worth $5.37B, up 1.2% from $5.31B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Geneva Advisors's Q4 2014 filing shows 121 new, 189 increased, 310 reduced and 120 closed positions. Its largest new stake was Idexx Laboratories: 488,650 shares worth $36.2M. The largest sale was LyondellBasell Industries, an estimated $73.1M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 15% a quarter earlier, followed by Financials and Industrials.
- Geneva Advisors's largest Q4 2014 buy was Idexx Laboratories: 488,650 shares worth $36.2M.
- Geneva Advisors added most to Alibaba in Q4 2014, an estimated $45.7M increase.
- Geneva Advisors's biggest Q4 2014 reduction was LyondellBasell Industries, cutting an estimated $73.1M.
- Geneva Advisors fully exited Community Health Systems in Q4 2014, selling an estimated $13M.
- Geneva Advisors's ten largest holdings make up 20% of its $5.37B portfolio in Q4 2014.
- Geneva Advisors opened 121 new positions and closed 120 in Q4 2014.
- Geneva Advisors's portfolio value rose 1.2% quarter-over-quarter to $5.37B.
Based on Geneva Advisors's 13F filing for Q4 2014, filed 2 Feb 2015.